A number of firms have modified their ratings and price targets on shares of Stemline Therapeutics (NASDAQ: STML) recently:

  • 11/11/2019 – Stemline Therapeutics had its price target lowered by analysts at Wedbush from $20.00 to $17.00. They now have an “outperform” rating on the stock.
  • 11/11/2019 – Stemline Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
  • 11/6/2019 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/30/2019 – Stemline Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 10/26/2019 – Stemline Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $11.00 price target on the stock. According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
  • 10/23/2019 – Stemline Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/30/2019 – Stemline Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.

STML stock traded up $0.16 during mid-day trading on Tuesday, hitting $10.63. 510,674 shares of the company were exchanged, compared to its average volume of 623,461. The business has a 50 day simple moving average of $9.62 and a 200-day simple moving average of $12.74. The stock has a market capitalization of $496.78 million, a PE ratio of -3.56 and a beta of 1.35. Stemline Therapeutics Inc has a 1-year low of $7.82 and a 1-year high of $18.22.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. The company had revenue of $13.33 million for the quarter, compared to analyst estimates of $13.40 million. Sell-side analysts predict that Stemline Therapeutics Inc will post -1.77 earnings per share for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of Stemline Therapeutics by 16.6% during the second quarter. BlackRock Inc. now owns 3,152,812 shares of the biopharmaceutical company’s stock worth $48,301,000 after purchasing an additional 449,323 shares during the period. Vanguard Group Inc. increased its holdings in shares of Stemline Therapeutics by 14.0% during the second quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock worth $29,620,000 after purchasing an additional 237,768 shares during the period. C WorldWide Group Holding A S increased its holdings in shares of Stemline Therapeutics by 16.4% during the third quarter. C WorldWide Group Holding A S now owns 998,677 shares of the biopharmaceutical company’s stock worth $10,396,000 after purchasing an additional 140,595 shares during the period. Northern Trust Corp increased its holdings in shares of Stemline Therapeutics by 1.8% during the second quarter. Northern Trust Corp now owns 523,341 shares of the biopharmaceutical company’s stock worth $8,017,000 after purchasing an additional 9,112 shares during the period. Finally, Point72 Asset Management L.P. increased its holdings in shares of Stemline Therapeutics by 196.5% during the second quarter. Point72 Asset Management L.P. now owns 518,870 shares of the biopharmaceutical company’s stock worth $7,949,000 after purchasing an additional 343,870 shares during the period. 87.41% of the stock is currently owned by institutional investors.

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Article: What is a Fibonacci Channel?

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.